10-K: Neuraxis, Inc. Reports Financial Results for Fiscal Year 2024; Highlights Growth Strategy and Pipeline Development

Neuraxis, Inc. reports its 10-K filing, detailing its financial results for the fiscal year ended December 31, 2024, and outlining its business strategy focused on neuromodulation therapies, pipeline development, and regulatory compliance.

Summary

• Neuraxis, Inc., a medical technology company, released its 10-K filing for the fiscal year ended December 31, 2024.
• The company focuses on developing neuromodulation therapies, particularly the IB-Stim device for functional abdominal pain associated with IBS in adolescents.
• Neuraxis is also developing a Rectal Expulsion Device (RED) for evaluating neuromuscular function and rectal hypersensitivity.
• The company's mission is to provide solutions that create value and improve patient outcomes, especially in the pediatric population.
• Neuraxis has a history of operating losses, with a net loss of $8,241,501 in 2024 and $14,626,683 in 2023.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• Revenue increased by 9.2% to $2,685,925 in 2024, primarily due to volume growth from financial assistance programs.
• Gross profit increased by 7.8% to $2,323,923 in 2024, but gross margin decreased slightly due to the financial assistance programs.
• The company is pursuing additional FDA clearances for its IB-Stim device for other indications, such as chronic nausea, post-concussion syndrome, and cyclic vomiting syndrome.
• Neuraxis is subject to extensive regulation by the FDA and other authorities, including premarket clearance, manufacturing standards, and post-market surveillance.
• The company is also subject to healthcare fraud and abuse laws, data privacy and security laws, and environmental regulations.
• As of December 31, 2024, Neuraxis had cash on hand of $3,696,870 and a working capital surplus of $1,832,858.
• The company believes its existing cash will be sufficient to meet anticipated operating needs before the end of 2025.
• Management is committed to remediating material weaknesses in internal control over financial reporting.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's revenue growth and pipeline development, the company faces significant financial challenges, including operating losses and doubts about its ability to continue as a going concern. The sentiment is neutral, reflecting both positive and negative aspects.

Positives

• Net sales increased by 9.2% to $2,685,925 in 2024.
• Gross profit increased by 7.8% to $2,323,923 in 2024.
• The company is pursuing additional FDA clearances for its IB-Stim device for other indications.
• As of December 31, 2024, Neuraxis had cash on hand of $3,696,870 and a working capital surplus of $1,832,858.

Negatives

• The company incurred a net loss of $8,241,501 in 2024.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• Management is committed to remediating material weaknesses in internal control over financial reporting.

Risks

• The company's business and prospects depend entirely on its current products, IB-Stim and RED.
• The company has a history of incurring substantial operating losses.
• Clinical studies could be delayed or adversely affected by many factors, including difficulties in enrolling patients.
• The company may not be successful in achieving market acceptance of its products.
• Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of the company's products.
• The company may depend on single-source suppliers for some of its components.
• The company currently does not own a manufacturing facility and relies on a sole manufacturer for the production of its product.
• The company had material weaknesses in its internal control over financing reporting during the years ended December 31, 2024 and 2023, that are unremediated as of December 31, 2024.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it continues to pursue widespread insurance coverage of its IB-Stim and RED devices and seek FDA clearance of its device for other indications.

Management Comments

• Management believes that increased sales and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.

Industry Context

The document highlights the competitive landscape for therapies, including off-label drugs, psychological treatments, and other devices, while emphasizing Neuraxis's unique position in targeting the CNS through auricular nerves for functional bowel disorders and IBS.

Comparison to Industry Standards

• The document mentions competitors such as Masimo, which licenses the NSS-2 Bridge device, and other companies in the neuromodulation space.
• It also discusses approved drugs for adults with IBS, such as Rifaximin, Amitiza, Linzess, Plecanatide, and Eluxadoline, and devices like gammaCore and Transcranial Magnetic Stimulation.
• However, it emphasizes that Neuraxis has a unique position in targeting the CNS through auricular nerves for functional bowel disorders or IBS.

Management Changes

Legal Proceedings

• The company is involved in ongoing litigation related to claims arising out of operations in the normal course of business.
• A lawsuit initiated in 2019 by Ritu Bhambhani, M.D., was dismissed, and the plaintiffs appeal was denied.
• A related lawsuit initiated in 2022 by business entities owned by the plaintiffs is ongoing, with claims related to the RICO Act dismissed.
• In January 2024, Dr. Arturo Taca served notice to the Company that asserted an interest in its U.S. Patent No. 10,413,719 valued at $2,000,000 based on his own work in neurostimulation.

Related Party Transactions

• The company has demand notes receivable from its two founding shareholders, Christopher Robin Brown and Gary Peterson, related to the sale of common stock on January 1, 2016.
• The company has loans payable to Christopher Robin Brown, one of our founders and a member of our board of directors, related to funding needs for operations with original principal amounts of $55,000 and $50,000 each bearing interest at 15% per annum.
• Mr. Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to his appointment to the Board of Directors.
• John Seale, our former Chief Financial Officer, is also the managing partner of a third-party public accounting firm that provides contracted services to the Company.

Stakeholder Impact

• The company's ability to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by way of a public or private offering.
• The company is subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, and its stockholders could receive less information than they might expect to receive from more mature public companies.
• Because the Company is a smaller reporting company, it may take advantage of certain scaled disclosures available to it, resulting in holders of its securities receiving less Company information than they would receive from a public company that is not a smaller reporting company.

Next Steps

• The company plans to continue pursuing widespread insurance coverage of its IB-Stim and RED devices.
• The company plans to continue seeking FDA clearance of its device for other indications.
• Management is committed to remediating material weaknesses in internal control over financial reporting.

Key Dates

Keywords

IB-Stim, neuromodulation, IBS, FDA, medical device, PENFS, RED, revenue, clinical trials, Neuraxis